Trials / Completed
CompletedNCT02399410
Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis
BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- University Hospital, Ghent · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The Bev-IP trial is designed to assess the feasibility and efficacy of a combined treatment consisting of perioperative combination chemotherapy with the vascular endothelial growth factor A inhibitor bevacizumab and cytoreductive surgery with intraperitoneal oxaliplatin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | perioperative chemotherapy plus bevacizumab | preoperative and postoperative combination chemotherapy with bevacizumab |
| PROCEDURE | cytoreductive surgery | complete or nearly complete removal of synchronous or metachronous peritoneal carcinomatosis from CRC. |
| DRUG | Intraperitoneal Oxaliplatin | Pump-driven intraperitoneal administration of oxaliplatin |
Timeline
- Start date
- 2015-11-04
- Primary completion
- 2023-11-09
- Completion
- 2023-11-09
- First posted
- 2015-03-26
- Last updated
- 2024-01-30
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT02399410. Inclusion in this directory is not an endorsement.